I think the issue here is.... We've spoken about organizational mandates and our values and we are a company deeply focused on patient needs. We're here to represent the fact that the issue with the regulations is that the original intent of the PMPRB was to prevent abuse of patented drugs with respect to excessive pricing.
What's happening now is that these guidelines go well beyond this. You've heard multiple times from multiple people here today that they are highly complex. They have created a great deal of uncertainty and they will make it difficult for companies to make a sustainable contribution to commercialized medications in Canada.
That's the heart of the matter for us, and that's our concern.